Company: BIAF
Filing Date: 2025-05-27
Form Type: 424B5
Source: 0001641172-25-012410
Chunk: 17

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-27
Form: 424B5
Chunk 17
---
 agent in the sale of common stock. WallachBeth will be entitled to a commission in an amount equal to 3.0% of the gross proceeds from the sale of common stock offered hereby. In addition, we have agreed to reimburse WallachBeth for initial fees and disbursements related to its legal counsel in an amount not to exceed $40,000, in addition to up to $3,000 for each quarterly and annual bringdown. We estimate that the total expenses for the offering, excluding commissions payable to WallachBeth under the terms of the Sales Agreement, will be approximately $115,000.

Settlement for sales of common stock will generally occur on the first business day, or such shorter settlement cycle that is in effect under Exchange Act Rule 15c6-1 from time to time, following the date on which any sales are made or on some other date that is agreed upon by us and WallachBeth in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

In connection with the sale of the common stock on our behalf in this offering, WallachBeth will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of WallachBeth will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to WallachBeth against certain civil liabilities, including liabilities under the Securities Act or the Exchange Act, and to contribute to payments that WallachBeth may be required to make in respect of such liabilities.

The offering of our common stock pursuant to the Sales Agreement under this prospectus supplement will terminate upon the earlier of (i) the sale of all of our common stock provided for in this prospectus supplement or (ii) termination of the Sales Agreement as provided therein.

WallachBeth and its affiliates have provided, and may in the future provide, various investment banking and other financial services for us and our affiliates, for which services they have received, and may in the future receive, customary fees. WallachBeth served as: (i) the placement agent in connection with our sale of convertible bridge notes in 2021 and 2022, (ii) the underwriter for our initial public offering that closed on September 6, 2022; (iii) the placement agent for a registered direct offering and concurrent private placement consummated in March 2024; (iv) financial advisor and placement agent for